AMPK Alters Detrusor Contractility During Emptying in Normal Bladder and Hypertrophied Bladder with Partial Bladder Outlet Obstruction via CaMKKβ

Int J Mol Sci. 2019 May 29;20(11):2650. doi: 10.3390/ijms20112650.

Abstract

AMP-activated protein kinase (AMPK) has been implicated in contractility changes in bladders with partial bladder outlet obstruction (PBOO), but the role of AMPK in the contractile response of normal bladder remains unclear. We investigated the phosphorylation of AMPKα and expression of the involved upstream AMPK kinases (AMPKKs) in a model of bladders with PBOO and sought to determine whether the pharmacological inhibition of these two factors affected detrusor contractility in normal bladders, using female Sprague-Dawley rats. Cystometry and Western blot analysis were performed in rats that were subjected to PBOO induction or a sham operation. Cystometry was performed in normal rats that received selective inhibitors of AMPKα and Ca2+/calmodulin-dependent protein kinase kinase (CaMKKβ) (compound C and STO-609, respectively) at doses determined in the experiments. In the PBOO bladders, bladder weight and micturition pressure (MP) were higher and AMPKα phosphorylation (T172) and CaMKKβ expression was significantly reduced. Compound C and STO-609 increased MP. The increased contractile response in bladders with PBOO-induced hypertrophy was related to decreased CaMKKβ/AMPK signaling activity, and the pharmacological inhibition of this pathway in normal bladders increased detrusor contractility, implying a role of CaMKKβ/AMPK signaling in the bladder in the regulation of detrusor contractility.

Keywords: AMPK; CaMKKβ; muscle contraction; urethral obstruction; urinary bladder.

MeSH terms

  • AMP-Activated Protein Kinase Kinases
  • Animals
  • Benzimidazoles / pharmacology
  • Benzimidazoles / therapeutic use
  • Calcium-Calmodulin-Dependent Protein Kinase Kinase / antagonists & inhibitors
  • Calcium-Calmodulin-Dependent Protein Kinase Kinase / metabolism*
  • Female
  • Muscle Contraction*
  • Naphthalimides / pharmacology
  • Naphthalimides / therapeutic use
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Protein Kinases / metabolism*
  • Rats
  • Rats, Sprague-Dawley
  • Urinary Bladder / drug effects
  • Urinary Bladder / metabolism*
  • Urinary Bladder / physiology
  • Urinary Bladder / physiopathology
  • Urinary Bladder Neck Obstruction / drug therapy
  • Urinary Bladder Neck Obstruction / metabolism*
  • Urination*

Substances

  • Benzimidazoles
  • Naphthalimides
  • Protein Kinase Inhibitors
  • STO 609
  • Protein Kinases
  • Calcium-Calmodulin-Dependent Protein Kinase Kinase
  • AMP-Activated Protein Kinase Kinases